Advertisement Biocon Launches Haselmeier's Insulin Pen in India - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Biocon Launches Haselmeier’s Insulin Pen in India

Haselmeier has announced that Biocon has launched INSUPen® in India.

Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen, for use with Biocon’s insulin and insulin analogues.

The first launch of the INSUPen has taken place with Biocon’s Basalog® and Insugen® insulins.

Download this white paper to find out more.